Varian Receives CE Mark for ProBeam Proton Therapy System

Varian Medical has received the CE mark for its ProBeam proton therapy system, clearing the way for its use in the European Union.

The system is designed to treat certain types of cancer more precisely and with potentially fewer side effects than conventional radiation therapy, the Palo Alto, Calif., devicemaker says. That’s because proton beams can be controlled so their energy is deposited within the tumor site, rather than passing all the way through the patient, Varian adds.

The CE mark follows last week’s FDA 510(k) clearance and CE mark approval of the firm’s VitalBeam platform, which delivers advanced radiotherapy to cancer patients. — Michael Cipriano